Medicure Inc. · TSXV:MPH

Medicure — Investor Presentation (March 2015)

19 slides from Medicure's investor presentation, Mar 31, 2015

  1. Slide 1: Investor Presentation

    Investor Presenta,on Albert D. Friesen, PhD Dawson Reimer Chair & CEO President & COO March 31, 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements

  3. Slide 3: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-­‐ST eleva,on acute coronary syndrome (NSTE-­‐ACS). Dosag

  4. Slide 4: Medicure Inc. Overview

    Medicure Inc. Overview $3.5 Aggrastat Quarterly $3.0 Net Product Sales (CDN Millions) $2.5 $2.0 $1.5 $1.0 $0.5 Q1 Q2 Q3 Q4 Q1 Q1 Q4 Q2 Q3 $0.0 2013 2014 4

  5. Slide 5: Future Value Drivers

    Future Value Drivers • Additional regulatory studies • Penetrate Angiomax & Reopro Market • Established API Manufacture • Transdermal Aggrastat is in Development Tardoxal • New Product in Development for Motion Disorders * TARDOXAL is an experimental product that is not approved by the FDA * AGGRADE

  6. Slide 6: Aggrastat overview: launched by Merck in 1998

    § Launched by Merck in 1998 § U.S. rights acquired by Medicure in 2006 § I.V. platelet inhibitor; binds the GP IIb/IIIa receptor § Indicated for Acute Coronary Syndrome (ACS) § 41% reduction in death and MI in high-risk patients* § Patent expiration: June 2023 New FDA Approved High Bolus Dosin

  7. Slide 7: Competitive Positioning of Aggrastat

    Competitive Positioning of Aggrastat 7

  8. Slide 8: New US Hospitals Using Aggrastat

    New US Hospitals Using Aggrastat 8

  9. Slide 9: New Commercial Model Weekly Bag Demand

    New Commercial Model Weekly Bag Demand 9

  10. Slide 10: GPI Acquisition Costs

    $3,500 GPI Acquisition Costs $3,000 Aggrastat: 25 µg/kg § US healthcare system is bolus + 0.15 µg/kg/min financially stressed $2,500 Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min § Integrilin often one of the largest $2,000 Reopro: 0.25 mg/kg pharmacy line items $3,126.12 bolus + 0.125 µg/kg/min $

  11. Slide 11: Aggrastat Price vs. Angiomax

    Aggrastat Price vs. Angiomax $2,000 $1,781.60 Angiomax § 2001 – 2013 Angiomax replaced > 1/2 of GPIs in US $1,500 § Aggrastat short infusion is $890.80 alternative to Angiomax Angiomax $1,000 § Typical hospital savings: $100,000 - $1,500,000 / year $500 $247.29 $247.29 Aggrastat Aggrastat $0 Bolu

  12. Slide 12: SAVI PCI Study Design

    SAVI PCI Study Design Total ∼675 patients undergoing PCI (March Enrollment Update: ∼2/3 Complete) Choice of Oral Anti-Platelet(s) ASA and clopidogrel or prasugrel or ticagrelor I.V. Anti-Thrombin Unfractionated Heparin 50 U/kg 1:1:1 randomization Open-label Tirofiban HDB (short) Eptifibatide Tirofib

  13. Slide 13: SAVI PCI Clinical Study

    SAVI PCI Clinical Study § Aggrastat is the only GPI Approved with Short Infusion § Benefit of Short Infusion: • Poten,al for reduced bleeding while s,ll maintaining efficacy • Fits beier with contemporary medicine & facilitates outpa,ent PCI 0.5 hrs 1 - 2 hrs 12 - 24 hrs PCI SAVI PCI Tradi/onal Treat

  14. Slide 14: Apicore Transaction

    Apicore Transaction Deal Features: 1. Medicure receives fixed price options to buy 100% ownership until July 2017 2. Medicure receives 6.1% equity (5.3% fully diluted) Press Release: July 3, 2014 3. $22.5 Million share purchase & debt financing of Apicore structured by Medicure Medicure Acquires Min

  15. Slide 15: Apicore Background

    Apicore Background Year Revenue Commercial Products 2012 $5 Million 3 2013 $10.3 Million 3 2014 Not Disclosed 8 § API Manufacturer & ANDA Developer • Complex synthetic chemistry Somerset, New Jersey • Early & “first to file” generics • Secure, high quality production § History: • Opened US facilit

  16. Slide 16: Business Vision

    Business Vision Aggrastat Quarterly Net Product Sales $3.5 (CDN Millions) $3.0 § To build a large, stable, specialty pharmaceutical $2.5 company $2.0 § To further expand Aggrastat revenue $1.5 § To expand revenue with new commercial products $1.0 § To diversify company value $0.5 with new produc

  17. Slide 17: Key Financial Info

    Key Financial Info Expressed in CND Cap Structure As of April 27, 2015 Basic Total 12,523,980 Fully Diluted Total 14,494,470 Share Price $2.38 Market Cap $29,807,072 § Recent Financial Highlights Q1 • Net Revenue- $3.3 M • *Adjusted EBITA- $ 1.1 M • CFPS- $0.06 • EPS- $ 0.01 § 2015 Financial Focus

  18. Slide 18: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-­‐ST eleva,on acute coronary syndrome (NSTE-­‐ACS). Dosag

  19. Slide 19: Thank you.

    Thank you. Contact a Product Specialist Investor Rela/ons 1.800.509.0544 [email protected] 1.888.435.2220 (Ext. 231) For More Informa/on Analyst Coverage www.medicure.com www.aggrastat.com Andre Uddin Mackie Research 19

Medicure — Investor Presentation (March 2015) on 6ix